You are here

  • Home
  • Archive
  • Volume 22, Issue 9
  • Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile: A Phase 2 Trial

Article metrics

Article menu
Download PDFPDF
Ovarian Cancer
Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile: A Phase 2 Trial

 

Online download statistics by month:

Online download statistics by month: December 2018 to April 2024

AbstractFullPdf
Dec 2018800
Jan 20193603
Feb 20192600
Mar 20194200
Apr 20191001
May 20193100
Jun 20192001
Jul 20193303
Aug 20193401
Sep 20193403
Oct 20192202
Nov 20191201
Dec 20193000
Jan 20202902
Feb 2020600
Mar 20202600
Apr 20201000
May 20204000
Jun 20205600
Jul 20204100
Aug 20201400
Sep 20202101
Oct 20201600
Nov 20201000
Dec 20202403
Jan 20211900
Feb 20214000
Mar 20212400
Apr 20211200
May 2021700
Jun 2021002
Jul 2021200
Aug 2021202
Sep 2021600
Oct 20213100
Nov 20212200
Dec 20211200
Jan 20221400
Feb 20225600
Mar 20222400
Apr 20223200
May 20225500
Jun 20225600
Jul 20224900
Aug 20225300
Sep 20226501
Oct 20224400
Nov 20223000
Dec 20225200
Jan 20231200
Feb 20237201
Mar 20232200
Apr 20232400
May 20231500
Jun 20231600
Jul 20232603
Aug 20234301
Sep 20232401
Oct 20232100
Nov 20231400
Dec 20234000
Jan 20242801
Feb 2024800
Mar 20241000
Apr 20244200
Total1755033